Cargando…
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081989/ https://www.ncbi.nlm.nih.gov/pubmed/34974674 http://dx.doi.org/10.5217/ir.2021.00098 |
_version_ | 1784703113025814528 |
---|---|
author | Lee, Yoo Jin Kim, Seong-Eun Park, Yong Eun Chang, Ji Young Song, Hyun Joo Kim, Duk Hwan Yang, Young Joo Kim, Byung Chang Lee, Jae Gon Yang, Hee Chan Choi, Miyoung Myung, Seung-Jae |
author_facet | Lee, Yoo Jin Kim, Seong-Eun Park, Yong Eun Chang, Ji Young Song, Hyun Joo Kim, Duk Hwan Yang, Young Joo Kim, Byung Chang Lee, Jae Gon Yang, Hee Chan Choi, Miyoung Myung, Seung-Jae |
author_sort | Lee, Yoo Jin |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy. |
format | Online Article Text |
id | pubmed-9081989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Association for the Study of Intestinal Diseases |
record_format | MEDLINE/PubMed |
spelling | pubmed-90819892022-05-17 SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID Lee, Yoo Jin Kim, Seong-Eun Park, Yong Eun Chang, Ji Young Song, Hyun Joo Kim, Duk Hwan Yang, Young Joo Kim, Byung Chang Lee, Jae Gon Yang, Hee Chan Choi, Miyoung Myung, Seung-Jae Intest Res Statement Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy. Korean Association for the Study of Intestinal Diseases 2022-04 2022-01-05 /pmc/articles/PMC9081989/ /pubmed/34974674 http://dx.doi.org/10.5217/ir.2021.00098 Text en © Copyright 2022. Korean Association for the Study of Intestinal Diseases. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Statement Lee, Yoo Jin Kim, Seong-Eun Park, Yong Eun Chang, Ji Young Song, Hyun Joo Kim, Duk Hwan Yang, Young Joo Kim, Byung Chang Lee, Jae Gon Yang, Hee Chan Choi, Miyoung Myung, Seung-Jae SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID |
title | SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID |
title_full | SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID |
title_fullStr | SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID |
title_full_unstemmed | SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID |
title_short | SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID |
title_sort | sars-cov-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by kasid |
topic | Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081989/ https://www.ncbi.nlm.nih.gov/pubmed/34974674 http://dx.doi.org/10.5217/ir.2021.00098 |
work_keys_str_mv | AT leeyoojin sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT kimseongeun sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT parkyongeun sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT changjiyoung sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT songhyunjoo sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT kimdukhwan sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT yangyoungjoo sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT kimbyungchang sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT leejaegon sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT yangheechan sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT choimiyoung sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT myungseungjae sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid AT sarscov2vaccinationforadultpatientswithinflammatoryboweldiseaseexpertconsensusstatementbykasid |